Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:GKOSNASDAQ:NARINASDAQ:NXLNASDAQ:TMDX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGKOSGlaukos$100.32-2.0%$93.91$77.10▼$163.71$5.72B0.8736,575 shs1.88 million shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.39 million shsN/ANXLNexalin Technology$1.04-7.1%$1.38$0.59▼$4.49$17.87M4884,415 shs129,744 shsTMDXTransMedics Group$123.56-0.4%$114.23$55.00▼$177.37$4.18B2.11.37 million shs1.29 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGKOSGlaukos0.00%+2.70%+3.02%-1.66%-11.52%NARIInari Medical0.00%0.00%0.00%0.00%+76.03%NXLNexalin Technology0.00%-9.57%-14.05%-56.30%0.00%TMDXTransMedics Group0.00%-13.52%+0.18%+78.94%-15.35%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGKOSGlaukos4.4965 of 5 stars4.42.00.04.42.22.50.6NARIInari Medical0.2979 of 5 stars1.10.00.00.00.02.50.6NXLNexalin Technology1.7643 of 5 stars3.53.00.00.00.61.70.0TMDXTransMedics Group1.3222 of 5 stars1.42.00.00.01.52.51.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGKOSGlaukos 2.75Moderate Buy$134.6734.23% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideNXLNexalin Technology 3.00Buy$5.00380.77% UpsideTMDXTransMedics Group 2.80Moderate Buy$127.333.05% UpsideCurrent Analyst Ratings BreakdownLatest NXL, GKOS, TMDX, and NARI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/17/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$130.00 ➝ $150.006/17/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold6/4/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$125.00 ➝ $145.006/3/2025TMDXTransMedics GroupNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold5/9/2025TMDXTransMedics GroupOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$125.00 ➝ $130.005/9/2025TMDXTransMedics GroupPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$105.00 ➝ $125.005/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.005/1/2025GKOSGlaukosStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $115.005/1/2025GKOSGlaukosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$176.00 ➝ $115.00(Data available from 6/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGKOSGlaukos$383.48M14.95N/AN/A$13.91 per share7.21NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91NXLNexalin Technology$170K105.10N/AN/A$0.28 per share3.71TMDXTransMedics Group$441.54M9.46$1.65 per share75.09$6.81 per share18.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGKOSGlaukos-$146.37M-$2.37N/AN/AN/A-31.40%-10.66%-8.06%7/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ANXLNexalin Technology-$7.61M-$0.83N/A∞N/A-6,529.77%-277.92%-245.37%N/ATMDXTransMedics Group$35.46M$1.3690.8586.41N/A10.03%21.88%6.15%7/30/2025 (Estimated)Latest NXL, GKOS, TMDX, and NARI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025NXLNexalin Technology-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million5/8/2025Q1 2025TMDXTransMedics Group$0.29$0.70+$0.41$0.70$123.39 million$143.54 million4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGKOSGlaukosN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/ATMDXTransMedics GroupN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGKOSGlaukos0.096.495.62NARIInari MedicalN/A1.771.40NXLNexalin TechnologyN/A4.564.25TMDXTransMedics Group1.929.108.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGKOSGlaukos99.04%NARIInari Medical90.98%NXLNexalin Technology0.65%TMDXTransMedics Group99.67%Insider OwnershipCompanyInsider OwnershipGKOSGlaukos5.80%NARIInari Medical10.60%NXLNexalin Technology24.00%TMDXTransMedics Group7.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGKOSGlaukos78057.14 million53.83 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableNXLNexalin Technology317.18 million13.06 millionNot OptionableTMDXTransMedics Group21033.82 million31.46 millionOptionableNXL, GKOS, TMDX, and NARI HeadlinesRecent News About These CompaniesTransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Cornerstone Wealth Management LLCJune 21 at 4:05 AM | marketbeat.comBrokerages Set TransMedics Group, Inc. (NASDAQ:TMDX) PT at $125.11June 20 at 1:53 AM | americanbankingnews.comTransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by SG Americas Securities LLCJune 19 at 3:43 AM | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $150.00 at OppenheimerJune 19 at 1:19 AM | americanbankingnews.comBoasting A 18% Return On Equity, Is TransMedics Group, Inc. (NASDAQ:TMDX) A Top Quality Stock?June 18, 2025 | finance.yahoo.comTransMedics Group (NASDAQ:TMDX) Stock Price Down 4.9% - Should You Sell?June 18, 2025 | marketbeat.comTransMedics Group (NASDAQ:TMDX) Price Target Raised to $150.00June 17, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Is Investigating TransMedics Group, Inc. (TMDX) And Encourages Shareholders to ConnectJune 17, 2025 | accessnewswire.comTransMedics Group's (TMDX) Hold Rating Reiterated at Needham & Company LLCJune 17, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 17, 2025 | marketbeat.comHandelsbanken Fonder AB Sells 72,000 Shares of TransMedics Group, Inc. (NASDAQ:TMDX)June 16, 2025 | marketbeat.comBronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against TransMedics Group, Inc. (TMDX) And Encourages Shareholders to Reach OutJune 15, 2025 | accessnewswire.comPrice Over Earnings Overview: TransMedics GroupJune 13, 2025 | benzinga.comThese 24 Stocks Are Ripe for a Short SqueezeJune 12, 2025 | schaeffersresearch.comBronstein, Gewirtz & Grossman, LLC Encourages TransMedics Group, Inc. (TMDX) Stockholders to Inquire about Securities InvestigationJune 12, 2025 | accessnewswire.comMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayJune 12, 2025 | marketbeat.comTransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells $95,902.80 in StockJune 11, 2025 | insidertrades.comInsider Selling: TransMedics Group, Inc. (NASDAQ:TMDX) Insider Sells 686 Shares of StockJune 10, 2025 | marketbeat.comKuehn Law Encourages Investors of TransMedics Group, Inc. to Contact Law FirmJune 10, 2025 | globenewswire.comBronstein, Gewirtz & Grossman, LLC Announces an Investigation Against TransMedics Group, Inc. (TMDX) and Encourages Investors to Learn More About the InvestigationJune 10, 2025 | accessnewswire.comTransMedics Group, Inc. (TMDX): A Bull Case TheoryJune 9, 2025 | insidermonkey.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All Headlines3 Defense Stocks That Will Profit From a Golden DomeBy Chris Markoch | May 30, 2025View 3 Defense Stocks That Will Profit From a Golden DomeIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeAnalysts Think These Stocks Could More Than Double in ValueBy Nathan Reiff | May 23, 2025View Analysts Think These Stocks Could More Than Double in ValueMid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in MayBy Leo Miller | June 12, 2025View Mid-Cap Marvels: 3 Stocks That Crushed Sales Estimates in May3 High-Growth Stocks Traders Love and Investors Should WatchBy Chris Markoch | June 5, 2025View 3 High-Growth Stocks Traders Love and Investors Should WatchNXL, GKOS, TMDX, and NARI Company DescriptionsGlaukos NYSE:GKOS$100.32 -2.02 (-1.97%) Closing price 06/20/2025 03:59 PM EasternExtended Trading$100.14 -0.18 (-0.18%) As of 06/20/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Nexalin Technology NASDAQ:NXL$1.04 -0.08 (-7.14%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$1.06 +0.02 (+1.92%) As of 06/20/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.TransMedics Group NASDAQ:TMDX$123.56 -0.44 (-0.35%) Closing price 06/20/2025 04:00 PM EasternExtended Trading$123.00 -0.56 (-0.45%) As of 06/20/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas New All-Time Highs Coming for Broadcom? Wall Street Says Yes Smith & Wesson Stock Falls on Earnings Miss, Tariff Woes Marvell's New AI Chip Deals Capture Wall Street’s Attention Super Micro Computer Stock's Rally Backed by Strong Financials Forget the Fed: Home Depot Is the Real Gauge of the U.S. Consumer GE Aerospace Turns Engines Into Long-Term Profits 3 Reasons AMD Could Be the Hottest Stock of the Summer Analysts Keep Boosting Taiwan Semiconductor Stock—Here's Why Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
